<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Maylita Sari</style></author><author><style face="normal" font="default" size="100%">Kartika Misalina</style></author><author><style face="normal" font="default" size="100%">M. Yulianto Listiawan</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Role of Cyclooxigenase-2 Inhibitor in Basal Cell Carcinoma: A Literature Review</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Basal cell carcinoma.</style></keyword><keyword><style  face="normal" font="default" size="100%">Cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">Chemoprevention</style></keyword><keyword><style  face="normal" font="default" size="100%">Cox-2 inhibitor</style></keyword><keyword><style  face="normal" font="default" size="100%">Cyclooxygenase</style></keyword><keyword><style  face="normal" font="default" size="100%">Skin malignancy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">233-238</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;Basal cell carcinoma (BCC) is the most common skin malignancy worldwide. It has low mortality but can cause significant morbidity primarily due to local destruction. The incidence and associated cost are rising in recent years causing a burden in healthcare system. BCC incidence are continue to increase due to lack of effective chemopreventive option. Several risk factors are associated with the pathogenesis of BCC. One of the major risk factors of BCC is exposure to ultraviolet (UV) rays, hence the prevention strategy for this malignancy include avoidance of natural and artificial sources of UV radiation. However, these methods are still less than optimal in inhibiting the emergence of basal cell carcioma. In recent years, there is accumulating evidence that cyclooxygenase-2 (COX-2), may be involved in the pathogenesis of BCC. Several recent studies have shown that the use of cyclooxygenase-2 (COX-2) inhibitor drugs can prevent the development of nonmelanoma skin tumors including BCC. In this review, we described the potential of COX-2 inhibitors as chemoprevention for BCC.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Review Article</style></work-type><section><style face="normal" font="default" size="100%">233</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Maylita Sari, Kartika Misalina, M. Yulianto Listiawan*&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;Department of Dermatology and Venereology, Universitas Airlangga/ Dr. Soetomo General Academic Teaching Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lukman La Basy</style></author><author><style face="normal" font="default" size="100%">Djoko Santosa</style></author><author><style face="normal" font="default" size="100%">Retno Murwanti</style></author><author><style face="normal" font="default" size="100%">Triana Hertiani</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Uncover Itchy Leaves Ethnomedicine Usage: A Preliminary Study on Characterization and Bioactivity of Laportea Spp</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Characterization</style></keyword><keyword><style  face="normal" font="default" size="100%">Cox-2 inhibitor</style></keyword><keyword><style  face="normal" font="default" size="100%">DPPH radical scavenging activity.</style></keyword><keyword><style  face="normal" font="default" size="100%">Itchy leaves</style></keyword><keyword><style  face="normal" font="default" size="100%">Laportea decumana (Roxb.) Wedd</style></keyword><keyword><style  face="normal" font="default" size="100%">Laportea stimulans (L.f.) Gaud</style></keyword><keyword><style  face="normal" font="default" size="100%">Phytochemical profiles</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">286-295</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;&lt;em&gt;Laportea decumana&lt;/em&gt; (Roxb.) Wedd. and &lt;em&gt;Laportea&lt;/em&gt; stimulans (L.f.) Miq. (Urticaceae) or itchy leaves are endogenous plants from The Maluku Islands, Indonesia, which are used topically as analgesics by local people.&lt;strong&gt; Objective&lt;/strong&gt;: As part of a preliminary investigation on the itchy leaves, this study was conducted to provide information on their macroscopic and microscopic characteristics, phytochemical profiles, and bioactivities according to the ethnomedicinal usages. &lt;strong&gt;Materials and Methods: &lt;/strong&gt;The macroscopic examination was carried out on fresh leaves. The microscopic examination was carried out on leaf powder under a light microscope. The phytochemical analyses using TLC were conducted on those crude extracts and fractions. The bioactivity assays were conducted&lt;em&gt; in vitro&lt;/em&gt; as Cox-2 inhibitory and DPPH radical scavenging activities. Results: reveal similar characteristics in the macroscopic and microscopic properties of both &lt;em&gt;Laportea &lt;/em&gt;spp. leaves. Calcium oxalate crystals were observed in&lt;em&gt; L. decumana&lt;/em&gt; but not found in &lt;em&gt;L. stimulans.&lt;/em&gt; Both species have stomata with anisocytic type. More trichomes are found in the leaves of&lt;em&gt; L. decumana,&lt;/em&gt; yet smaller and easily detachable. TLC analyses exhibited slightly different profiles. The crude extracts and fractions at 10 μg/ml showed similar inhibitory percentages on Cox-2. The DPPH scavenging activities of the crude extracts and fractions of&lt;em&gt; L. decumana &lt;/em&gt;showed active moderate activity with an IC50 value &amp;lt; 250 μg/ml, while those of &lt;em&gt;L. stimulans&lt;/em&gt; showed moderate to weak potency with an IC50 value &amp;lt; 500 μg/ml. &lt;strong&gt;Conclusion: &lt;/strong&gt;Further exploration on Laportea spp. pharmacological activity is recommended to provide stronger evidence for its ethnomedicinal usage.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><accession-num><style face="normal" font="default" size="100%">06</style></accession-num><section><style face="normal" font="default" size="100%">286</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Lukman La Basy&lt;sup&gt;1,2&lt;/sup&gt;, Djoko Santosa&lt;sup&gt;3&lt;/sup&gt;, Retno Murwanti&lt;sup&gt;4&lt;/sup&gt;, Triana Hertiani&lt;sup&gt;3,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Pharmaceutical Sciences Doctoral Study Program, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, 55281, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Pharmacy Department, Stikes Maluku Husada, Maluku 97566, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>